

Antidepressants and suicide: 7,829 inquests in England and Wales, 2003-2020

Read, J.

Abstract

Background:

Antidepressant medications increase suicidality for some, or all, age groups. Some, or all, types of antidepressants are frequently used in suicides involving overdoses.

Methods:

The paper examines a previously unanalysed data set summarising 7,829 media reports of Coroners' Inquests in England and Wales that mention antidepressants, between 2003 and 2020.

Results:

The most frequently cited ADs were SSRIs (48.9%) and tricyclics (24.6%). The specific drugs cited most often were the SSRI drug citalopram (19.8%) and the tricyclic drug amitriptyline (17.5%). Of 2,329 cases of death by overdose, 933 (40.1%) were overdoses of ADs, 512 of which (54.9%) did not involve other substances. A further 929 were overdoses of unnamed medicines, a proportion of which may have been ADs. The ADs most frequently named were amitriptyline (186), and citalopram (86).

Limitations:

The data set, which relies primarily on archives of local newspapers, is incomplete and therefore underestimates the total numbers involved. The accuracy of coroners' verdicts is not perfect.

Conclusions:

If preventing suicide is a primary reason for prescribing antidepressants, this data set includes several thousand people for whom the drugs clearly did not work. About 1,000 people used

the drugs that were supposed to alleviate their depression to kill themselves. Systematic analyses of all Inquests would be more informative. Meanwhile, reducing the overprescribing of these relatively ineffective and, for some, lethally dangerous substances is suggested, to reduce suicides.

Keywords:

Antidepressants; SSRIs; suicide; overdose; inquest

INTRODUCTION

An epidemic of antidepressant prescribing

In the U.S.A. 8% of the population aged over 12 used antidepressants [ADs], in a given month, between 1999-2002, rapidly increasing to 13% (37 million adults) by 2011-2014 (Pratt et al., 2017). During 2015–2018, use was higher among women (17.7%) than men (8.4%) and highest in women over 60 (24.3%) (Brody and Gu, 2020). In the U.K. annual AD prescribing doubled in ten years, so that by 2017-2018, 7.3 million adults (17% of adults) were prescribed ADs, over 12 months, in England alone; with higher rates for women, older people and people in deprived areas (Taylor et al., 2019). Prescribing has continued to increase at roughly the same rate during the COVID-19 pandemic, with 20.5 million antidepressant drugs prescribed in England between October and December 2020, a 6% increase compared with the same quarter in 2019/20 (Taylor et al., 2019) Currently 2.1 billion doses are prescribed annually by GPs to a population of 52 million people in England, which means 11% of individuals are taking at least one AD on any day (Heald et al., 2020). Similarly, high prescription rates are found in Australia, Belgium, Canada, Iceland, Portugal and Sweden (O.E.C.D., 2021).

In the UK 54% of prescribed ADs are SSRIs, followed by SNRIs (23%) and Tricyclics (23%) (Druggist, 2020). Monoamine-Oxidase Inhibitors (which were about as lethal as Tricyclics in terms of overdoses) now account for less than 1% of prescriptions. Table 1 reports the most prescribed antidepressant drugs in the UK.

Table 1

Antidepressants prescribed in the UK, 2019.

Drug	Type	Items prescribed (millions)
Sertraline	SSRI	16.7
Citalopram	SSRI	14.0
Amitriptyline	Tricyclic	13.9
Mirtazapine	NaSSA	9.6
Fluoxetine	SSRI	6.8
Venlafaxine	SNRI	4.6
Duloxetine	SNRI	2.6
Paroxetine	SSRI	1.3
Escitalopram	SSRI	1.2
Trazodone	'atypical'	1.2

Efficacy and adverse effects

This epidemic of prescribing has occurred despite efficacy and safety concerns. Less than half of early trials found ADs superior to placebo (Khan et al., 2002; Turner et al., 2008). This lack of difference between ADs and placebos is particularly frequent in non-industry studies (Khan and Brown, 2015; Moncrieff, 2015). One meta-analysis found that 'the overall effect of new-generation antidepressant medications is below recommended criteria for clinical significance' with no benefit compared to placebo except for 'patients at the upper end of the very severely depressed category' (Kirsch et al., 2008). A more recent meta-

analysis, of 131 placebo-controlled trials, confirmed that the overall effect size falls short of ‘clinical significance’ and concluded that ‘The harmful effects of SSRIs versus placebo for major depressive disorder seem to outweigh any potential small beneficial effects’ (Jakobsen et al., 2017).

High rates of adverse effects in the biological domain include: nausea, impotence, insomnia, diarrhoea, dry mouth, dyspepsia, and sweating (Moncrieff and Stockman, 2019; Moret et al., 2009; Uher et al., 2009). High rates of adverse effects in the personal and interpersonal domains have also been found. In a UK survey of nearly 1,500 AD users, 44% reported that ADs affected their sex lives, 27% their ability to work or study, and 21% their relationships with family or friends (Read et al., 2017). A sample of 1,829 AD recipients, in New Zealand, reported the following adverse effects: sexual difficulties - 62%, emotional numbing - 60%, drowsiness - 58%, dry mouth - 58%, weight gain - 56%, withdrawal effects - 55%, feeling not like oneself - 52%, agitation - 47%, reduction in positive feelings - 42%, and caring less about others - 39% (Read et al., 2018). The most significant recent development is that after decades of denial and minimisation by bodies such as the Royal College of Psychiatrists in the UK (Burn and Baldwin, 2018) and the American Psychiatric Association (2010), it is now acknowledged that withdrawal effects from antidepressants are often severe and can last for months (Davies and Read, 2019; Hengartner et al., 2019; Horowitz and Taylor, 2019).

Do antidepressants prevent or cause suicidality?

Given the paucity of evidence that ADs reduce depression significantly better than placebo it would be surprising if the drugs reduced suicidal thinking or prevented suicides. Some have sought to explain reductions in national suicide rates in terms of increased antidepressant prescribing (Gusmão et al., 2013). Correlation, however, does not equal causation, and there

are many other possible explanations for falling suicide rates. More recently, researchers have found no relationship between national suicide rates and AD prescribing rates (Amendola et al., 2021).

There is pervasive research evidence that, rather than reducing suicidal ideation and suicide, ADs can increase them for some patients. There is disagreement, however, as to whether this disturbing outcome is limited to certain age groups or types of people. In 2003 most ADs were banned by the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) from use with children (under 18), because of drug company studies showing they were not only ineffective but were significantly more likely to lead to suicidal behavior than placebo (Ho, 2012). The findings had been 'suppressed by the manufacturers for years' (Boseley, 2003).

In 2006 GlaxoSmithKline informed doctors in Britain that paroxetine (Seroxat) was more likely than placebo to cause suicide attempts in adults as well as children (Boseley, 2006). At the time paroxetine was the best-selling AD in Britain. Table 1 shows that it is still prescribed more than a million times a year, despite this warning.

In 2004, the U.S. Food and Drug Administration (FDA) required a 'black box warning' for all AD drug types (including fluoxetine) for people under 18:

Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in short-term studies in children and adolescents with Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of [Insert established name] or any other antidepressant in a child or adolescent must balance this risk with the clinical need. Patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior.

The warning has recently been confirmed as being ‘firmly rooted in solid data, whereas attempts to claim the warning has caused harm are based on quite weak evidence’ (Spielman et al., 2020).

In 2006, the FDA extended the warning to adults aged up to 25 years (Ho, 2012). In 2009 an FDA meta-analysis of 372 randomized placebo-controlled trials found that the risk of ‘suicidality and suicidal behavior’ associated with AD use relative to placebo was significantly increased among people 25 or younger, but reduced among those aged 65 or more. For those aged 26 to 64 the drugs made no significant difference (Amendola et al., 2021).

Researchers, based at the Nordic Cochrane Centre and the University of Copenhagen in Denmark argued, however, in the Journal of the Royal Society of Medicine, that:

While it is now generally accepted that ADs increase the risk of suicide and violence in children and adolescents (although many psychiatrists still deny this), most people believe that these drugs are not dangerous for adults. This is a potentially lethal misconception (Bielefeldt et al., 2016).

Their argument was based on their own review of 13 double-blind, placebo-controlled trials involving citalopram, escitalopram, fluoxetine, paroxetine, sertraline or venlafaxine, which found that these drugs ‘double the risk of suicidality and violence’. The researchers added:

There can be little doubt that we underestimated the harms of antidepressants... it [is] well documented that the drug companies underreport seriously the harms of antidepressants related to suicide and violence, either by simply omitting them from the reports, by calling them something else or by committing scientific misconduct.

In 2014 NICE seemed to believe all age groups are at risk of increased suicidality from ADs:

Due to evidence for a small but significant increase in the presence of suicidal thoughts in the early stages of antidepressant treatment, several NICE guidelines (including depression in adults, depression in adults with a chronic physical health problem and depression in children and young people) advise monitoring for this when antidepressants are prescribed. (NICE, 2014)

In the largest survey of AD users to date, in New Zealand, 39% of 1,555 people reported ‘suicidality’ as an effect of taking the drugs (Read et al., 2014). Of these, 53% categorised the suicidality as ‘mild’, 27% as ‘moderate’, and 20% as ‘severe’. Suicidality was greater among younger people, and those who had been on the drugs more than three years. A similar survey, with respondents from 38 countries, produced similar results. Of 953 people, 42.5% reported suicidality as a result of the ADs and 25% described the suicidality as ‘severe’. Again, suicidality was greater among younger people, and those on ADs for over three years (Read and Williams, 2018).

Two conservative conclusions from all this are (i) ADs increase the risk of suicide for a large proportion of people, and (ii) there is little evidence that they decrease the risk of suicide.

Antidepressants as the mechanism of suicide

A 2001 review reported that tricyclics had become ‘second only to analgesics as the commonest drug taken in fatal drug overdose’ (Kerr et al., 2001), with an average 268 people in Britain dying this way annually. Dothiepin and amitriptyline were identified as the most lethal. The number of deaths from ‘drug poisoning by antidepressants’ registered in England and Wales has increased 36% in ten years, from 381 in 2010 to 517 in 2020 (Office of National Statistics, 2021), when SSRIs contributed 165 (led by Citalopram). Tricyclics contributed 192 (mostly Amitriptyline) and ‘Other’ amounted to 219 (predominantly

Mirtazapine and Venlafaxine). ADs exceeded benzodiazepines (476) and antipsychotics (143). These three drugs combined constituted 25% of all drug poisonings, despite being prescribed to improve mental health.

NICE notes that between 1988 and 2014, 10% of ‘self-poisoning in young people aged 10 to 24 years in England involved ADs. Furthermore:

Between 2006 and 2016, for suicide by self-poisoning in people in England who had been in contact with mental health services in the previous year, 33% used opiates or opioids, 11% antipsychotic drugs, 9% tricyclic antidepressants, 9% selective serotonin re-uptake inhibitors (SSRIs) or serotonin and noradrenaline re-uptake inhibitors (SNRIs) and 7% paracetamol and opiate combinations.

It seems clear that although the old tricyclics are more dangerous in relation to overdosing than SSRIs and SRNIs (Lane et al., 1995), these newer drugs can also be used to kill oneself. The most recent NICE (2021) statement on the matter reads:

Tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) have the highest toxicity in overdose. Among TCAs, dosulepin has particularly high toxicity, while lofepramine has relatively low toxicity. . . . Venlafaxine and mirtazapine are less toxic than TCAs, but have a higher toxicity compared to selective serotonin reuptake inhibitors (SSRIs). . . . Duloxetine has low toxicity in overdose. . . . SSRIs have a low toxicity when taken in overdose, but they have been reported to prolong the QTc interval. Citalopram and escitalopram are associated with a greater tendency for cardiac toxicity than other SSRIs. However, their toxicity is modest and possibly insignificant.

Aims of this paper

This article uses a pre-existing database of media reports of 7,829 Inquests involving ADs, from 2003 to 2020, to try to shed more light on the relationship between these drugs and suicidality and on the use of ADs in lethal overdoses.

METHOD

Procedure

The database analysed in this study was compiled by someone who wishes to remain anonymous. This person has given permission for the database to be used for this publication. The person has read and approved the paper. The raw data is accessible, unanalysed, on <http://antidepaware.co.uk> .

Data collection started in 2013, initially covering reports of Inquests in England and Wales for the previous ten years. Data for each subsequent year, up to 2020, was then added. The UK Google search engine was used to find local and national media articles about Inquests referencing suicide and concomitant use of ADs. Further details of how the press reports were located and subsequently recorded is available at <http://antidepaware.co.uk/inquest-reports>. Initially, all press reports were available via the website, but some have since been removed by the publisher, probably due to archiving of data.

To locate the historical reports (years 2003 to 2013), Internet searches were conducted, in 2014, using combinations of the keywords “inquest”, “coroner”, “antidepressant” & “medication”. After 2013, the same search routine was conducted on a daily or weekly basis, using the search filters “past 24 hours” or “past week”. Data collection ended in 2020.

The following data was recorded in the Microsoft Excel spreadsheet provided to the authors: year of Inquest, name (surnames removed on the website, or names removed altogether at request of relatives), gender, occupation, age, location, antidepressant, cause of death, coroner’s verdict, and ‘relevant factors’. AD involvement was recorded using the name of the specific drug if reported or as ‘antidepressants’ if that term was used without naming the drug. Furthermore the category ‘MfD - Medication for Depression’ was used ‘where the report refers to “medication for depression” or similar’ (<http://antidepaware.co.uk>).

Coroners are independent judicial officers, appointed by the local authority, and are either doctors or lawyers responsible for investigating the cause of deaths. . . . The Coroner is expected to open an inquest where there is reasonable suspicion that the deceased has died a violent or unnatural death, where the cause of death is unknown or if the deceased died while in custody or state detention (Crown Prosecution Service, 2021).

The cause of death was as reported in the original media source. Recently, there has been some pressure from charities for newspapers not to report methods of suicide. Where method was not reported, “took his/her life” was recorded. If the coroner’s verdict was not reported in the media article it is coded in the data set as ‘not known’. ‘Relevant factors’ consists of additional information (from one to ten words) discovered in the reports deemed relevant to explain the coroners’ verdict or cause of death.

In ‘narrative’ verdicts the circumstances are recorded without a formal verdict, in statements which do not attribute cause to individuals. An ‘open’ verdict means the jury confirms the death is suspicious, but is unable to reach any other verdict. Some research suggests that many ‘open’ verdicts are recorded in suicide cases where intent cannot be established (Linsley et al., 2001). Table 2 presents one randomly selected example for each year from 2003 to 2020.

Table 2

Random examples from the data set.

Antidepressant	Cause of Death	Verdict	Relevant Factors
ADs	overdose of ADs & alcohol	narrative	homeless alcoholic
ADs	overdose of ADs, painkillers & alcohol	‘misadventure’	history of depression and had received treatment
ADs	hanged	‘suicide’	hoarded ADs - user of cocaine & alcohol - eating disorder

MfD (changed)	struck by tube train	'suicide'	info from interview with [family member]
MfD	stabbed himself	'suicide'	on leave from MH unit
Citalopram	hanged	'suicide'	overdose on Citalopram shortly before death
MfD	drowned in river	'suicide'	post-mortem showed MfD
MfD	struck by train	'suicide'	on leave from MH unit
Citalopram "	hanged	not known	had been prescribed 20mg of Citalopram
MfD	struck by train	'suicide'	MH trust criticised by coroner
ADs	jumped from bridge	narrative	prescribed ADs & anti-psychotics
ADs (stopped)	struck by train	'suicide'	prescribed ADs 3 wks before death, then stopped taking them
ADs	drowned in river	'open'	overdosed on ADs 3 days before death
MfD	overdose of methadone	'accidental'	had told staff he was receiving medication for depression
MfD	struck by train	'suicide'	did start to take his medication again a week before he died
ADs	hanged	'suicide'	given ADs by his doctor and was signed off work
MfD	overdose of drugs	'drug-rel'	depressed...took legal prescription drugs
Amitriptyline	overdose of Amitriptyline	'drug-rel'	fatal levels of Amitriptyline...not prescribed

Accuracy check

The source of the data, mostly local newspaper reports, was accessed (via <http://antidepaware.co.uk/inquest-reports>) and checked, for one randomly selected case from each year. For seven of the 18 years, the selected source report was no longer accessible, largely due to the archiving of newspaper reports more than 12 years old. In these cases, the next accessible report, alphabetically, was used.

All 18 cases were accurately reported in the data set in relation to age, gender, cause of death and coroner's verdict. Specific ADs (3) and use of the word 'antidepressants' (5) were also accurately recorded. The category 'MfD' (10) was defined on the website as referring to

cases ‘where the report refers to “medication for depression” or similar’. Examples typically referred to ‘depression’ and either ‘medication’ ‘treatment’ or ‘mental health team/unit’, rather than explicitly stating ‘medication for depression’, so may have included some cases not involving ADs.

RESULTS

Sample characteristics

Of the 7,829 cases in the data set, 5115 (65.3%) were male and 2714 (34.7%) were female. The mean age was 41.2 years (SD = 15.1), with a range from 10 to 97 years. Children (under 18) accounted for 2.3% of the total (184), and adults over 65 for 6.0% (462). There was no significant difference in the mean age of the males and females, overall. However, 76 of the 118 cases aged 16 or less were girls (64.4%). Prisoners made up 5.8% of the sample. The majority of these 451 prisoners were men (91.8%).

Table 3 lists the more common occupations of the 4485 cases where occupation was reported, most commonly students, unemployed, teachers, armed forces, nurses and engineers.

Table 3

Most common occupations* of the 4485, where occupation was reported.

Occupation	n
University/college student	270
Unemployed/redundant	174
Teacher/head teacher/teacher assistant	124
Soldier/navy/RAF	99
Nurse	96
Engineer	93
School student	76
Shop assistant/worker	76
Labourer/builder/construction worker	74
Businessman/woman	65
Care worker	55

Farmer	47
Police officer	46
Doctor	44
Factory/warehouse worker	39
IT/computer worker/consultant/engineer	38
Company director/manager	36
Cleaner/window cleaner	32
Musician	31
Chef	30
Lawyer/solicitor/barrister	29
Hairdresser/barber	26
Carer	25
University lecturer/researcher/professor	25
Lorry/HGV driver	22
Mechanic	22
Civil servant	20
Postal worker	20
Scientist/researcher	19
Carpenter/joiner	18
Decorator	17
Electrician	17
Warehouse worker	17
Gardener	16
Plumber	15
Mental health staff #	14
Support worker	14
Artist	13
Landscape gardener	13
Actor/actress	11
Pharmacist	10
Social worker	10

*includes 'ex ...' 'retired ...' 'redundant ...' & 'unemployed ...'

psychologists, psychiatrists, psychiatric nurses

The number of cases per year increased over time, ranging from 230 (2005) to 701 (2019).

Which antidepressants?

In most instances (77.7%) the drugs were reported either as 'medications for depression' (44.1%) or 'antidepressants' (33.6%). Specific ADs were named 1,839 times, including 138 (7.4%) cases involving more than one AD. Table 4 shows that the most frequently cited ADs were SSRIs (48.9%) and tricyclics (24.6%). The specific drugs cited most often were the

SSRI citalopram (19.8%), the tricyclic amitriptyline (17.5%) and mirtazapine, a noradrenergic and specific serotonergic antidepressant (NaSSA) (15.8%).

Table 4

Types of antidepressants cited in the reports.

Antidepressant		Percentage of total sample (7,829)
unnamed 'medications for depression' ... 'or similar' #	3454	44.1%
unnamed 'antidepressants'	2630	33.6%
		Percentage of named antidepressants (1,860)
SSRI	909	48.9%
citalopram	368	19.8%
fluoxetine/prozac	266	14.3%
sertraline	229	12.3%
seroxat/paroxetine	34	1.8%
escitalopram	11	0.6%
fluvoxamine	1	0.1%
TRICYCLIC	457	24.6%
amitriptyline	325	17.5%
dothiepin/dosulepin	90	4.8%
nortriptyline	18	1.0%
clomipramine	15	0.8%
imipramine	6	0.3%
doxepin	2	0.1%
trimipramine	1	0.1%
NaSSA	293	15.8%
mirtazapine	293	15.8%
SNRI	161	8.7%
venlafaxine/effexor	142	7.6%
duloxetine	19	1.0%
ATYPICAL	37	2.0%
trazodone	34	1.8%
bupropion/zyban	3	0.2%
MAOI	3	0.2%
phenelzine	2	0.1%

tranylcypromine	1	0.1%
Two or more antidepressants*	138	7.4%

includes 'treatment for depression' etc (see Accuracy Check section)

*most commonly: amitriptyline & mirtazapine - 16, mirtazapine & citalopram— 12, amitriptyline & nortriptyline - 11

SSRI – selective serotonin reuptake inhibitor

SNRI – serotonin-norepinephrine reuptake inhibitor

NaSSA – noradrenergic and specific serotonergic antidepressant

MAOI - monoamine oxidase inhibitors

New and changed prescriptions

A few reports commented on how recently people had been started on ADs before they died.

The 196 shortest time periods are reported in Table 5.

Table 5

Mention of recency of starting antidepressants.

Time period	n
'recently'	53
1 month	20
'a few weeks'	13
3 weeks	13
2 weeks	13
1 week	20
'a few days'	12
6 days	3
5 days	9
4 days	10
3 days	10
2 days	9
1 day	11

In 427 reports mention was made, under 'relevant factors,' of changes to ADs shortly before death, including 296 'stopped'/'withdrawn', 10 'reduced', 71 'increased' and 50 'changed' (from one AD to another).

Causes of death

Table 6 shows that when the data set is analysed by ‘Cause of Death’ (regardless of verdict), death by imbibing one or more substances is the second most common mechanism (29.8%), after hanging (34.7%). Of these 2,329 cases of death following the consumption of a dangerous substance, 933 (40.1%) were overdoses of ADs (see Table 7). A further 929 (39.9%) were overdoses of unnamed medicines, a proportion of which may have been ADs. Table 7 reports that of the 933 deaths definitely following AD overdoses, 512 (54.9%) involved ADs without any other substances.

The ADs most frequently named as being used in an overdose (sometimes in combination with other ADs or other substances) were the tricyclic drug amitriptyline (186) and the SSRI, citalopram (86) (see Table 8). In 89 cases the overdose involved other psychiatric drugs, primarily ‘anti-anxiety’/‘sleeping pills’ (63) and ‘anti-psychotic’ drugs (23)

Table 6
Causes of death.

Cause of death	n	%
Hanged	2718	34.7%
Overdose	2329	29.8%
ODs definitely involving ADs	933	11.9%
Struck By ...	552	7.1%
Train/Tube	455	
Lorry, Car, Bus, Vehicle	97	
Jumped/Fell	440	5.6%
Drowned	359	4.9%
Shot Self	126	1.6%
Set Self On Fire	40	0.5%
Electrocuted	14	0.2%

Table 7
The role of antidepressants in 2329 suicides by overdose.

Role of antidepressants	n	%
Definitely one or more ADS	933	40.1%
Just AD(s)	512	22.0%
AD + alcohol	95	
AD + non-psych med(s)	184	
AD + other psych med(s)	54	
AD + illegal drugs	14	
AD + combination of above	74	
Possibly ADs	929	39.9%
Unspecified medicines	799	
Unspecified meds + alc/drugs	130	
Definitely not ADs	467	20.0%
Non-psych meds	264	
Illegal drugs	84	
Psych meds (not ADS)	32	
Poison	18	
Combination of above	69	

Table 8

Antidepressants named at least ten times in suicides by overdose.

Anti-depressant	Type	Over-doses	alone	with other anti-depressants	with other anti-depressants + other substances	with other substances*
amitriptyline	tricyclic	186	102 (55%)	7 (4%)	9 (5%)	68 (37%)
citalopram	SSRI	86	27 (31%)	11 (13%)	6 (7%)	42 (49%)
dothiepin	tricyclic	80	60 (75%)	3 (4%)	0	17 (21%)
venlafaxine	SNRI	63	34 (54%)	5 (8%)	2 (3%)	22 (35%)
mirtazapine	NaSSA	42	15 (36%)	1 (2%)	6 (14%)	20 (48%)
fluoxetine	SSRI	41	14 (34%)	1 (2%)	0	26 (62%)
sertraline	SSRI	28	14 (50%)	2 (7%)	1 (4%)	11 (39%)
clomipramine	tricyclic	13	10 (77%)	0	0	3 (23%)

*predominantly painkillers/opiates, alcohol, other psychiatric drugs, other prescription drugs, and heroin

Verdicts

Nearly half (45.3%) of the coroners' verdicts were 'suicide' (Table 9). Of these 3543 definite suicide cases, the majority (84.5%) involved either unnamed 'antidepressants' (1209, 34.1%) or 'medications for depression' (1776, 50.1%). The most frequently named drugs were citalopram (88), fluoxetine (75), sertraline (73) and amitriptyline (71).

Besides ADs failing to prevent these suicides, the ADs provided the mechanism for suicide in 254 cases. In 92 of these overdoses involving ADs another substance was also consumed, most often painkillers (37) and other psychiatric drugs (24). In the remaining 162 suicides ADs alone were the instrument of death. The drugs most frequently named were amitriptyline (45, including 25 without other substances), dothiepin (31, 28) and the SSRI citalopram (17, 7).

In a further 115 cases unspecified prescription drugs were used to overdose. It is unknown how many of these were ADs or other psychiatric drugs. Table 10 shows that many deaths as a result of taking an overdose of ADs are also recorded under other verdicts besides 'suicide'.

Table 9
Coroners' verdicts.

Verdict	n	%
Suicide ¹	3543	45.3%
Narrative	1166	14.9%
Not Known ²	1060	13.5%
Open	859	11.0%
Accidental	468	6.0%
Drug-Related ³	372	4.8%
Misadventure	288	3.7%
Alcohol-Related ³	67	0.9%
Natural Causes	23	0.3%
Road Traffic Collision	20	0.3%

1 includes 96 'murder-suicides'

2 not reported in media article

3 includes 53 'drug *and* alcohol related'

Table 10

Overdoses using antidepressants leading to most common verdicts.

Verdict	Antidepressants alone	Antidepressants plus other substances	Unnamed prescription drugs*
'Suicide' (3543)	162	97	193
'Narrative' (1166)	89	68	96
Not known (1060)	26	25	53
'Open' (859)	76	93	80
'Accidental' (468)	64	57	93
'Drug-related' (372)	20	36	52
'Misadventure' (288)	36	34	65

*with or without other substances

Murder-suicides

Of the 96 cases where suicide was immediately preceded by murder, the victim (when identified) was most frequently a wife (15) or a son/daughter (16). Unspecified 'antidepressants' were cited in 49 of the cases and 'medication for depression' in 33. The only ADs to be named in more than two cases were mirtazapine (3) and citalopram (3). In seven cases the ADs had recently been stopped, in six cases they had been changed and in two they had been increased. In only one murder-suicide case did the suicide involve overdosing with an AD.

Electroconvulsive therapy

Four people had been receiving electroconvulsive therapy as well as ADs. Two hanged themselves, one suffocated herself, and another died, in 2020, from a 'post-ECT seizure'.

DISCUSSION

Lessons to be learned

We present this unique data set with few firm conclusions. We do not know in how many cases the problems for which the drugs were prescribed contributed to the deaths. Nor can

we tell in how many of the 7,829 cases ADs actively contributed to the deaths. We can say, however, that ADs failed to lift the depression sufficiently to prevent 2,718 hangings, 2,329 overdoses, 440 cases of jumping or falling to one's death, 126 cases of shooting oneself and 40 of setting oneself on fire. In none of the 3,543 cases for which the coroner reached a clear 'suicide' verdict, can ADs be reasonably described as effective.

The second conclusive finding is that at least 933 people used ADs to kill themselves, with or without other substances. In a further 929 cases it is impossible to know whether the unspecified 'prescribed medicine' used to overdose was an AD. So in somewhere between 40.1% and 80.0% of the overdoses, the medicines prescribed to help prevent suicide were used to commit suicide. It is important to note that SSRIs, which were marketed as much safer than tricyclics in terms of lethal toxicity in overdose situations, can also kill you, with or without alcohol and other substances (see Table 10). 'Easy access to lethal means among people at risk (e.g. firearms, medications)' is, unsurprisingly, officially considered a risk factor for suicide, and 'Limited access to lethal means among people at risk' is, of course, a protective factor (Centers for Disease Control and Prevention, 2021). And yet our response to millions of depressed or suicidal people, rather than trying to keep them away from lethal means, is to prescribe it to them in a bottle.

It is possible that in some cases coming off or reducing ADs caused, or contributed to, the suicide, perhaps via the depression returning after successful alleviation thereof by the ADs, perhaps because of unbearable withdrawal effects. In no cases, however, was stopping or reducing ADs mentioned as a 'cause of death'. Of the 306 cases where 'relevant factors' mentioned that ADs had been 'stopped'/'withdrawn' or reduced, most did not provide information on whether this contributed to the deaths. Three did state the person felt worse after stopping. Three reported that the person stopped because the drugs were not working.

Twenty one reported that the drugs had made the person feel worse, either emotionally or because of adverse physical effects.

This data set provides almost no evidence that the withdrawal effects, which occur in about half of people when stopping or reducing ADs, and are frequently severe (Davies and Read, 2019; Read and Davies, 2019), contributed to the deaths. In three cases it was mentioned, under ‘relevant factors’ that the ADs had been stopped ‘suddenly’ or ‘abruptly’. One case reported: "she could have suffered unpleasant withdrawal symptoms". It must be pointed out, however, that until 2019 the true extent and severity of ADs’ withdrawal effects were unrecognised by medical professionals (see Introduction) so would have been unlikely to have been mentioned by coroners.

The data set is also unable to address the issue of whether the increased suicidality caused by ADs occurs only ‘in the early stages of antidepressant treatment’ (NICE, 2014). Table 5 documents 196 cases where ADs had been started within one month or ‘recently’. The two large scale online surveys mentioned earlier, however, both found that the drugs caused more suicidality in respondents who had been taking the drugs for more than three years (Read et al., 2014; Read and Williams, 2018). It is possible that both are true. There could be a brief acute increase in suicidality which subsides, only to be followed by a gradual increase in hopelessness and suicidality over months or years as one realises (a) that the drugs don’t work, and/or (b) that they have multiple adverse effects (such as emotional numbing and sexual dysfunction) and/or (c) that it is very difficult to come off them without severe withdrawal effects. Future research, with better designs than online surveys, is required to address this vitally important issue

Limitations

The collator of the data set acknowledges, on the website, some important limitations:

The first thing to say about these lists, comprising in total more than 7800 deaths linked to antidepressants, is that all the information here has been found on the Internet, mostly in the archives of local newspapers. I have had no privileged access to any other material. I have limited myself to inquest reports dating from the beginning of 2003 and concerning deaths in England and Wales.

Secondly, this list is far from complete. In fact, it could be subtitled “the tip of the iceberg”. For every inquest report that I was able to include, there was at least another where toxicology was completely excluded from the report, or where medication was hidden behind phrases such as “she sought help for depression” or “he saw his GP”. Then there are the local newspapers that remove reports from their archives after a certain period, those that do not have search facilities, and those that do not report the inquests in the first place. (<http://antidepaware.co.uk/inquest-reports>)

In England and Wales there were 5,691 suicides in 2019 (4303 in men and boys) (Iacobucci, 2020). There were 32,000 Inquests opened in 2020 (Ministry of Justice, 2021). So ‘tip of the iceberg’ seems an accurate description of the data set summarised here. In the absence of any comprehensive analyses of either suicides or Inquests in relation to psychiatric drugs, by the government or academia, we should be grateful for the efforts of the person concerned, and try to learn from this work what we can, while acknowledging its limitations.

NICE (2019) guidelines for media reporting of suicides states that best practice includes ‘avoiding presenting detail on methods’. So, besides the newspaper reports from which the data set was sourced, there are presumably many other reports of cases involving AD overdoses where that fact was not reported.

It is a limitation that ‘Medication for Depression’ was broadly defined to include ‘or similar’. As acknowledged in the Methods section, this probably led to the inclusion of cases where the ‘treatment’ or ‘medication’ in question was something other than ADs. Working in

the opposite direction are the 929 overdose cases involving unspecified medications, many of which might have been ADs.

Another limitation is the accuracy of the coroner's verdicts. A review of 593 cases where researchers classified deaths as suicide, only 385 (65.4%) received a suicide verdict from the coroner. Furthermore 'deaths from poisoning and drowning were the least likely to be given suicide verdicts' (Palmer et al., 2005) This suggest the data set summarised in the current paper underestimates the frequency with which ADs are used in overdosing.

Conclusions

The data set we have summarised here confirms the findings of drug trials showing that ADs are ineffective for many people . The reports document the deaths of several thousand people who killed themselves despite being on ADs, and more than a thousand who actually used the drugs that were supposed to alleviate their depression to kill themselves.

These findings, combined with the inevitable shortcomings of a data set generated by one person's unfunded, voluntary efforts, illustrates how much could be learned from a properly funded, systemic review of Inquest reports and national suicides with a focus on psychiatric medications. Since 2009, coroners in England and Wales have had to report cases where it may be possible to prevent future deaths. In 2017 researchers examined 500 such reports and found 99 in which medicines were mentioned, including 17 involving ADs. The researchers noted that the reports 'are often addressed to local bodies, but this could mean that wider lessons are lost' (Ferner et al., 2018). When the researchers asked the local bodies (eg NHS trusts) how they had responded to the reports, 66 of the 99 replied:

We analysed 201 separate actions proposed or taken to address the 160 concerns expressed by coroners. Staff education or training was the most common form of action taken (44/201). Some organisations made changes in process (24/201) or policy

(17/201), and some felt existing policies were sufficient to address some concerns (22/201).

We concur with the researchers' conclusions (Ferner et al., 2019) that:

Coroners' concerns are often of national importance but are not currently shared nationally. Only a minority of responses to coroners' reports concerning medicines are in the public domain. Processes for auditing responses and assessing their effectiveness are opaque. Few of the responses appear to provide robust and generally applicable ways to prevent future deaths.

It has to be said, on behalf of the thousands of people whose deaths provide the basis for this paper, that doctors and professional bodies have an ethical responsibility to avoid prescribing or recommending treatments that are no more effective than placebo for most patients, which increase suicidality in many, and which constitute an effective method for killing oneself.

Declaration of Competing Interest

The author declares no financial conflicts of interest.

Professor Read is Chair of the International Institute for Psychiatric Drug Withdrawal (www.iipdw.org)

Acknowledgments

I (JR) acknowledge the many hours spent by the person who accumulated this large data set.

I also acknowledge the tireless commitment of Dr Ed White to supporting people struggling to come off antidepressants, despite his suffering with severe withdrawal symptoms himself. Dr White liaised with the data gatherer to facilitate the initiation of this paper. Sadly, Ed died before the completion of the paper.

References

- Amendola, S., Plöderl, M., Hengartner, M. (2021). Did the introduction and increased prescribing of antidepressants lead to changes in long-term trends of suicide rates? *Eur J Pub. Health* 31, 291-297.
- American Psychiatric Association (2010). Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. A.P.A., Washington D.C.
- Antonuccio, D., Healy, D. (2012). Relabeling the medications we call antidepressants. *Scientifica*, 965908.
- Bielefeldt, A., Danborg, P., & Gøtzsche, P. (2016). Precursors to suicidality and violence on antidepressants: systematic review of trials in adult healthy volunteers. *J. Royal Soc. Med.* 109, 381-392.
- Boseley, S (2003). Drugs for depressed children banned. *The Guardian*, 10 Dec. <https://www.theguardian.com/science/2003/dec/10/drugs.sciencenews>
- Boseley, S. (2006). Antidepressant linked to suicide risk in adults. *The Guardian*, 13 May. <https://www.theguardian.com/society/2006/may/13/socialcare.medicineandhealth>
- Brody, D., Gu, Q. (2020). Antidepressant use among adults: United States, 2015–2018. National Centre for Health Statistics, Data Brief 377.
- Burn, W., Baldwin, D. (2018). Letter to the editor. *The Times*, Feb. 24. <https://www.thetimes.co.uk/article/86afb2fc-18c7-11e8-a427-78e8af199a96>
- Centers for Disease Control and Prevention. (2021). Suicide prevention. 13 May. <https://www.cdc.gov/suicide/factors/index.html>
- Crown Prosecution Service. (2021). Coroners. <https://www.cps.gov.uk/legal-guidance/coroners>. C.P.S., London.
- Davies, J., Read, J. (2019). A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based? *Addict. Behav.* 97, 111-121.
- Druggist. (2020). Online, data source: OpenPrescribing.net, EBM DataLab, University of Oxford. <https://druggist.online/most-common-antidepressants-uk/>
- Ferner, R., Easton, C., Cox, A. (2018). Deaths from medicines: a systematic analysis of coroners' reports to prevent future deaths. *Drug Saf.* 41, 103-110.
- Ferner, R., Ahmad, T., Babatunde, Z., Cox, A. (2019). Preventing future deaths from medicines: responses to coroners' concerns in England and Wales. *Drug Saf.* 42, 445-451.
- Food and Drug Administration. (2004). Class suicidality labeling language for antidepressants. FDA, Silver Spring, Maryland. https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/20031s045,20936s0201bl.pdf
- Gusmão, R., Quintão, S., McDaid, D., Arensman, E., Van Audenhove, C., Coffey, C., Värnik, A., Värnik, P., Coyne, J., Ulrich, Hegerl. (2013). Antidepressant utilization and suicide in Europe: an ecological multi-national study. *PLoS One* 8, e66455.
- Heald, A., Stedman, M., Davies M., Livingston, M., Taylor, D., Gadsby, R. (2020). Antidepressant prescribing in England: patterns and costs. *Prim. Care Compan. C.N.S. Disord.* 22, 19m02552.
- Hengartner, M., Davies, J., Read, J. (2019). Antidepressant withdrawal – the tide is turning. *Epidemiol. Psychiatr. Sci.* 29, e52
- Ho, D. (2012). Antidepressants and the FDA's Black-Box warning: determining a rational public policy in the absence of sufficient evidence. *Virtual Ment.* 14, 483-488.
- Horowitz, M., Taylor, D. (2019). Tapering of SSRI treatment to mitigate withdrawal symptoms. *Lancet Psychiatry* 6, 538-546.
- Iacobucci, G. (2020). Suicide rates continue to rise in England and Wales. *Br. Med. J.* 370, m3431.

- Jakobsen, J., Katakam, K., Schou, A., Hellmuth, S., Stallknecht, S., Leth-Møller, K., . . . Gluud, J. (2017). Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. *BMC Psychiatry* 17, 58.
- Kerr, G., McGuffie, A., Wilkie, S., Tricyclic antidepressant overdose: a review. (2001). *Emerg Med J* 18, 236-241.
- Khan, A., Brown, W. (2015). Antidepressants versus placebo in major depression: an overview. *World Psychiatry* 14, 294-300.
- Khan, A., Khan, S., Brown, W. (2002). Are placebo controls necessary to test new antidepressants and anxiolytics? *Int. J. Neuropsychopharmacol.* 5, 193-197.
- Kirsch, I., Deacon, B., Huedo-Medina, T., Scoboria, A., Moore, T., Johnson, B. (2008). Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. *PLoS Med.* 5, e45.
- Lane, R., Baldwin, D., Preskorn, S. (1995). The SSRIs: advantages, disadvantages and differences. *J. Psychopharmacol.* 9 (2 Suppl), 163-178.
- Linsley, K., Schapira, K., Kelly, T (2001). Open verdict v. suicide - importance to research. *Br. J. Psychiatry* 178, 465-468.
- Ministry of Justice (2021). Coroners statistics 2020: England and Wales. Ministry of Justice, London.
<https://www.gov.uk/government/statistics/coroners-statistics-2020/coroners-statistics-2020-england-and-wales>
- Moncrieff, J. (2015). Antidepressants: misnamed and misrepresented. *World Psychiatry* 14, 302-303.
- Moncrieff, J., Stockmann, T. (2019). What psychiatric drugs do by class. In: Guy, A., Davies, J., Rizq, R. (Eds.), *Guidance for psychological therapists: Enabling conversations with clients taking or withdrawing from prescribed psychiatric drugs.* APPG for Prescribed Drug Dependence, London.
- Moret, C., Isaac, M., Briley, M. (2009). Problems associated with long-term treatment with selective serotonin reuptake inhibitors. *J. Psychopharmacol.* 23, 967-974.
- National Health Service Business Services Authority (2021). Medicines used in Mental Health: England April 2015 to December 2020. 2021; Mar 4.
<https://nhsbsa-opendata.s3.eu-west-2.amazonaws.com/mumh-2021-q3-narrative-v001.html>
- NICE (2014). Suicide prevention: optimising medicines and reducing access to medicines as a means of suicide. Key therapeutic topic [KTT24].
- NICE (2019). Suicide prevention: Quality standard [QS189]. NICE, 10 Sep.
<https://www.nice.org.uk/guidance/qs189/chapter/Quality-statement-3-Media-reporting>
- NICE (2021). Depression: How toxic are antidepressants in overdose?
<https://cks.nice.org.uk/topics/depression/prescribing-information/toxicity-in-overdose/>
- OECD, (2021). OECD Health Statistics 2021. Pharmaceutical Market, 28 Jun.
https://stats.oecd.org/Index.aspx?DataSetCode=HEALTH_PHMC
- Office of National Statistics, (2021). Drugs related to drug poisoning in England and Wales: 2020 registrations. ONS, August 3.
<https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodrugpoisoninginenglandandwales/2020>
- Palmer, B., Bennewith, O., Simkin, S., Cooper, J., Hawton, K., Kapur, N., Gunnell, D. (2015). Factors influencing coroners' verdicts: an analysis of verdicts given in 12 coroners' districts to researcher-defined suicides in England in 2005. *J. Pub. Health* 37, 157-165.
- Pratt, L., Brody, D., Gu, Q. (2017). Antidepressant use among persons aged 12 and over: United States, 2011-2014. *NCHS Data Brief* 283, 1-8.

- Read, J., Cartwright, C., Gibson, K. (2018). How many of 1,829 antidepressant users report withdrawal symptoms or addiction? *Int. J. Ment. Health Nurs.* 27, 1805-1815.
- Read, J., Cartwright, C., Gibson, K. (2014). Adverse emotional and interpersonal effects reported by 1,829 New Zealanders while taking antidepressants. *Psychiatry Res.* 216, 67-73.
- Read, J., Davies, J. (2019). What do we know about withdrawal? In: Guy, A., Davies, J., Rizq, R. (Eds.), *Guidance for psychological therapists: Enabling conversations with clients taking or withdrawing from prescribed psychiatric drugs*. APPG for Prescribed Drug Dependence, London.
- Read, J., Gee, A., Diggle, J., Butler, H. (2017). The interpersonal adverse effects reported by 1,008 users of antidepressants; and the incremental impact of polypharmacy. *Psychiatry Res.* 256, 423-427.
- Read, J., Williams, J. (2018). Adverse effects of antidepressants reported by a large international cohort: Emotional blunting, suicidality, and withdrawal effects. *Curr. Drug Saf.* 13, 176-186.
- Spielmanns, G., Spense-Sing, T., Parry, P. (2020). Duty to warn: Antidepressant black box suicidality warning is empirically justified. *Front Psychiatry* Feb 13, 11:18.
- Taylor, S., Annand, F., Burkinshaw, P., Greaves, F., Kelleher, M., Knight, J., Perkins C, Tran A, White M, Marsden J. (2019). Dependence and withdrawal associated with some prescribed medicines: an evidence review. Public Health England, London.
- Turner, E., Matthews, A., Linardatos, E., Tell, R., Rosenthal, R. (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. *New Eng. J. Med.* 358, 252-60.
- Uher, R., Farmer, A., Henigsberg, N., Rietschel, M., Mors, O., Maier, W., . . . Aitchison, K. (2009). Adverse reactions to antidepressants. *Br. J. Psychiatry* 195, 202-210.